Allium Medical wins Chinese marketing urological stent nod

Stent Photo: Shutterstock
Stent Photo: Shutterstock

The approval means that the company's agreement with a Chinese distributor will go into effect.

The share price of Allium Medical Ltd. (TASE: ALMD) rose 12.5% earlier this week following an announcement that the company had obtained marketing approval for its urological stent in China. Under the terms of a previously signed distribution agreement, a Chinese company will now order NIS 88 million worth of products from Allium Medical over eight years (NIS 11 million a year). Allium Medical believes that sales will begin this year. The surge in the company's share price boosted its market cap to NIS 88 million.

Allium Medical also announced that it had obtained marketing approval in Russia for its gynecological product for treatment of pelvic floor prolapse.

Allium Medical is a multidisciplinary medical devices company that develops urological stents and gynecological surgical solutions and sells them worldwide, while also developing complex implants that have not yet reached the sales stage.

Allium Medical's revenue from its urological and gynecological products has been growing slowly but steadily in recent years. The company posted NIS 7.7 million in revenue in 2017, 8% more than in 2016. If the Chinese distributor does make the expected orders, it is likely to have a substantial effect on the company.

Allium Medical has consistently lost money as a result of its investments in its more complex products, including NIS 22 million in 2017, most of it in operating loss. While the products being sold give the company's its stability, most of its current value comes from the potential of its "dream products." The leading such product as of now is a device for preventing embolisms in surgery. This product has already received marketing approval, and the company is looking for a strategic partner or buyer for it. The product has had approval for prevention of embolisms in the common carotid artery for a few months, and approval was also obtained two months ago for the same product for prevention of embolisms in the peripheral artery. The company said on that occasion that this approval was likely to lead to a deal, but no advanced negotiations for a deal have been announced so far, and obviously no such deal has been signed.

Allium Medical has added two more products to its portfolio in recent years: a sleeve surgery product for treatment of diabetes and obesity and a product for replacement of the mitral valve - one of the most attractive medical devices markets. These two products are in animal trials, while the product for diabetes and obesity is scheduled to enter human trials this year.

As of the end of 2017, Allium Medical had NIS 22 million in cash, after spending NIS 18.4 million on current activity during the year.

Allium Medical CEO Asaf Alperovitz said, "The Chinese market represents a huge opportunity for us, both because of its size and the trends in it and because of cooperation and the distribution agreement with our distributor in China, which has decades of experience and specialization in the urological market in China, plus broad geographic deployment there, both direct and through a sub-distributor. This distributor also has a widespread network of connections with leading urologists in China, some of whom participated in the company's clinical workshops in Germany and Italy. These urologists have expressed great enthusiasm about the company's products, which constitute a safe and effective alternative to surgical procedures and short-term solutions. In accordance with Chinese culture and medicine, doctors and patients in China strongly prefer minimally invasive solutions in the long term to surgical procedures, and some of the company's stent systems can be implanted in a clinic outside hospitals. The doctors believe that this will make the products accessible to additional territories and market segments beyond the main cities. Due to the combination of these factors, we believe that our stent systems have very significant clinical and commercial potential in this market."

Published by Globes [online], Israel business news - www.globes-online.com - on May 11, 2018

© Copyright of Globes Publisher Itonut (1983) Ltd. 2018

Stent Photo: Shutterstock
Stent Photo: Shutterstock
Eilat Ramon Airport Credit: Sivan Farag Eilat Municipal Spokesperson Russian airline to kick-start int'l flights from Eilat's Ramon airport

Russian airline Red Wings is to launch direct flights between Eilat's Ramon airport and Moscow and Sochi in Russia starting June 12.

High-tech credit: Shutterstock 8,300 tech employees left Israel after start of war

Amid increased relocation, Israel's tech workforce has contracted for the first time in over a decade, the Israel Innovation Authority reports.

Donald Trump  credit: Shutterstock Israel can't escape impact of tariffs

Even if Israel obtains relief from the tariff imposed on it by US President Trump, it will feel the global effects of the trade war, analysts say.

Shekel versus US dollar  credit: Tali Bogdanovsky US market slide shakes shekel

The shekel weakened significantly against both the US dollar and the euro at the opening of foreign exchange trading today.

Arik Faingold credit: Nati Levi Israeli autonomous frontend co AutonomyAI raises $4m

Led by Arik Faingold, the founder of cybersecurity unicorn Pentera, AutonomyAI offers a platform that learns and understands the full organizational context and generates code that can be deployed directly to the production environment.

British Airways aircraft  credit: Shutterstock/Jarek Kilian Tel Aviv - London fares to fall as British Airways resumes flights

From June there will be 20-32 weekly flights operated on the popular Tel Aviv - London route by foreign airlines - British Airways, Wizz Air and easyJet.

Partner Partner forms int'l business diivision

The division will be headed by former Bezeq International VP Global Business Nissan Arieh.

Caesarstone kitchen credit: Caesarstone Caesarstone bucks Nasdaq as tariffs boost potential

The Israeli quartz countertop manufacturer company has fallen on hard times due to Chinese rivalry but tariffs could boost its revenue.

ZIM ship credit: ZIM Trump's tariffs torpedo ZIM's share price

ZIM's share price fell 16.4% on Wall Street on Thursday and a further 7.2% on Friday, closing with a market cap of $1.5 billion, wiping out all its gains in 2025.

Israeli apartments Credit: Shutterstock Apartments sold and rented

A selection of recent real estate deals in Israel in Tel Aviv, Holon, Rehovot, Kiryat Tivon, Shlomi and Beersheva.

THAAD anti missile system credit: The US Army Ralph Scott Wikimedia US deploys more THAAD, Patriot batteries in Israel - report

Amid rising regional tensions the US is bolstering Israel's air defense, Saudi state-owned TV channel Al Arabiya reports.

Tel Aviv Stock Exchange credit: Shutterstock TASE tumbles in Wall Street's wake

Dual-listed stocks have again been hard hit, but the banks are also down sharply.

Donald Trump and Benjamin Netanyahu credit: Avi Ohayon Netanyahu due in Washington to discuss tariffs

According to news website Axios, Prime Minister Benjamin Netanyahu will be the first leader to meet President Trump after the latter's announcement of sweeping import tariffs.

Yoni Assia CEO eToro Credit: PR eToro defers IPO amid market turmoil

The online trading platform had planned to begin meetings with investors this week.

Minister of Finance Bezalel Smotrich credit: Shlomi Yosef Smotrich meets wrong man in Washington

Minister of Finance Bezalel Smotrich tried to persuade Secretary of the Treasury Scott Bessent to soften the tariff blow on Israel - only Bessent isn't responsible for the matter.

Unframe founders credit: Yossi Yarom Israeli AI enterprise platform co Unframe raises $50m

Unframe’s turnkey AI solutions enable companies to solve any enterprise AI use case at scale with fully functional, customized AI solutions for businesses in a matter of hours, rather than months.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018